Lithium prophylaxis of bipolar illness. The value of combination treatment.
Br J Psychiatry
; 164(2): 208-14, 1994 Feb.
Article
en En
| MEDLINE
| ID: mdl-7909713
Using a longitudinal life-table analysis, we assessed the efficacy of lithium alone, administered within the context of a naturalistic clinical setting, by calculating the probability of patients remaining free of an affective episode (manic or depressive) over a five-year course. In addition, for those who suffered a manic or depressive relapse, we attempted to analyse the subsequent course of patients who suffered a manic/hypomanic or depressive relapse and were then restabilised on lithium plus either a neuroleptic, carbamazepine, or a benzodiazepine, or lithium plus an antidepressant. Lithium alone offered an average 83% probability against an affective relapse after one year, 52% after three years, and 37% after five years. For patients who failed on lithium alone, it appeared that combination treatment offered greater protection against subsequent affective relapse than the initial course on lithium alone.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Psicotrópicos
/
Trastorno Bipolar
/
Litio
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Psychiatry
Año:
1994
Tipo del documento:
Article
Pais de publicación:
Reino Unido